5 registrations that name cinnamon as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 5 registrations
Status
Phase
All 5 registrations
RecruitingNCT07743073
The Effects of Ceylon Cinnamon (Cinnamomum Verum) Supplementation on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Intensity Among Adult Individuals With Painful Diabetic Peripheral Neuropathy
No phase
JAWAD AHMAD ABU-SHENNAR
About 164 people
Started Feb 1, 2026
In plain words A study of cinnamon in people 18 and older, run by JAWAD AHMAD ABU-SHENNAR. It plans to enroll about 164 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Painful Diabetic Peripheral Neuropathy.
Age ≥ 18years diagnosed with PDPN
With documented T2DM
The exclusion criteria are on the listing.
What it tests, as registered
Ceylon Cinnamon Supplement
Registered summary
Background: Painful diabetic peripheral neuropathy (PDPN) is a severe, disabling complication of type 2 diabetes mellitus (T2DM), closely associated with insulin resistance, chronic neuroinflammation, and oxidative stress. Plant-based dietary supplements, particularly Ceylon cinnamon (Cinnamomum verum), contain bioactive compounds with potential anti-diabetic, antioxidant, and neuroprotective properties. The full summary is on the listing.
Where, as registered
No US site; Jordan (1).
RecruitingNCT06164613
Use of Cinnamomum Verum for Induction of Labor. Double Blind Randomized Clinical Trial
Phase 2
Universidad Nacional Autonoma de Honduras
About 70 people
Started Dec 4, 2023
In plain words A Phase 2 study of cinnamon in female participants 14 to 45, run by Universidad Nacional Autonoma de Honduras. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 14 to 45; healthy volunteers accepted. Conditions: Labor Onset and Length Abnormalities; First Birth.
Delivery of an informed consent form signed and dated by parents or guardian and patient
Declared willingness to comply with all study procedures and availability for the duration of the study.
provision of appropriate consent and assent
Willingness and ability to participate in study procedures
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cinnamomum Verum oil extract; Placebo
Registered summary
The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated. The full summary is on the listing.
Where, as registered
No US site; Honduras (1).
RecruitingNCT07429227
Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.
No phase
Casa di Cura Dott. Pederzoli
About 15 people
Starts Mar 2026 (estimated)
In plain words A study of cinnamon in people 30 to 70, run by Casa di Cura Dott. Pederzoli. It plans to enroll about 15 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 70. Conditions: Acute Coronary Syndromes (ACS).
1\. Signing of informed consent
2\. Diagnosis of Acute Coronary Syndrome (ACS)
3\. Age 30-70
The exclusion criteria are on the listing.
What it tests, as registered
Tea tree (Melaleuca alternifolia), Cinnamon (Cynnamomum zeylanicum) bark, Clove carnation (Eugenia caryopyllus) flowers, Red thyme (Thymus vulgaris) plant
Registered summary
The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT07757399
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy
No phase
Jerash Private University
About 900 people
Starts Aug 1, 2026 (estimated)
In plain words A study of cinnamon in people 18 and older, run by Jerash Private University. It plans to enroll about 900 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Type 2 Diabetes Mellitus; Painful Diabetic Peripheral Neuropathy (PDPN).
Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months.
Confirmed diagnosis of painful diabetic peripheral neuropathy (PDPN).
Age between 18 and 65 years.
Able to provide written informed consent and willing to comply with the study protocol, supplement intake, and educational sessions.
The exclusion criteria are on the listing.
What it tests, as registered
Ceylon Cinnamon (Cinnamomum verum) Supplement; Matching Placebo; Self-Efficacy-Based Educational Program
Registered summary
This randomized controlled trial aims to evaluate the therapeutic effects of pure Ceylon cinnamon (Cinnamomum verum) supplementation combined with a structured self-efficacy-based educational program on glycemic control, lipid profiles, and neuropathic pain in adult patients with type 2 diabetes mellitus (T2DM) and painful diabetic peripheral neuropathy (PDPN). The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07315412
Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC
No phase
Fenerbahce University
About 75 people
Starts Dec 10, 2025 (estimated)
In plain words A study of cinnamon in people 18 to 80, run by Fenerbahce University. It plans to enroll about 75 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Postoperative Nausea and Vomiting (PONV); Peritoneal Metastases From Colorectal Cancer; Intraperitoneal Chemotherapy.
Adults aged 18 years or older undergoing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Able to communicate, understand study instructions, and provide written informed consent.
No known allergy or intolerance to ginger, mint, or cinnamon.
Able and willing to chew gum for 15 minutes.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Ginger-Mint Chewing Gum; Cinnamon Chewing Gum
Registered summary
This randomized controlled clinical trial aims to evaluate the effectiveness of chewing gum with different natural flavors in reducing postoperative nausea and vomiting (PONV) following Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Adult patients undergoing PIPAC will be randomly assigned to one of three groups: (1) ginger-mint flavored gum, (2) cinnamon flavored gum, or (3) control group with standard postoperative care only. Participants in the intervention arms will chew one piece of gum for 15 minutes in the post-anesthesia care unit (PACU). The full summary is on the listing.